5- other GLP-1 trials in Parkinsons have been statistically negative or the results unclear, 6- the study was conducted in only very early Parkinsons cases, 7- the data, if replicable, may not be generalizable to all GLP-1 agonist drugs or to all subtypes of Parkinsons, and 8- the drug Lixisenatide requires a DAILY injection
Read the full article here: #POLB #FT #Metabolic #Disease #Obesity #OralDrug #Pill #Weightloss #GLP1 To view or add a comment, sign in *Microbiome Research Alert: Your Past Medications Are Still Rewiring Your GutYears Later!* New findings from the Estonian Biobank study are shaking up *microbiome* research
What gets me really excited is its another option in our toolbox that lands us in double-digit weight loss for individuals struggling with obesity and diabetes, Horn said during a presentation
CJC-1295 and Ipamorelin interact with growth hormone signaling through complementary mechanisms
He's the only doctor I will ever use for anything cosmetic from now on
Do color-changing eye drops work